ArticleClinical and translational radiation oncology2026
Longitudinal changes in NT-proBNP after breast cancer radiotherapy: clinical determinants of its trajectory and association with cardiac dysfunction (BACCARAT study).
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Radiotherapy (RT) for breast cancer (BC) may induce subclinical myocardial injury. Longitudinal trajectories of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of myocardial stress, remain insufficiently characterized. We aimed to assess changes in NT-proBNP over 2 years after RT, identify clinical and treatment-associated factors, and evaluate associations with cancer therapy-related cardiac dysfunction (CTRCD). Methods: NT-proBNP was measured before RT, at RT completion, and at 6 and 24 months among 101 BC patients treated with adjuvant RT without chemotherapy. Echocardiography was performed longitudinally, and CTRCD was defined according to 2022 ESC Cardio-Oncology guidelines. Factors associated with NT-proBNP trajectories were analyzed using linear mixed-effects models. Logistic regression assessed associations between NT-proBNP and CTRCD. Results: NT-proBNP remained stable at the end of RT and at 6 months but increased at 24 months (β = 0.147, p < 0.0001; +16%). Baseline NT-proBNP was strongly associated with follow-up levels. Hypercholesterolemia (β = 0.252, p = 0.01), slightly moderate hypofractionated RT (20 × 2.35 Gy; β = 0.372, p = 0.0008), and aromatase inhibitor therapy (β = 0.258, p = 0.019) were independently associated with higher NT-proBNP at 24 months, whereas cardiac dose metrics were not. Seventeen patients developed CTRCD. NT-proBNP > 400 ng/L at 24 months was associated with CTRCD (OR = 6.5, 95% CI 1.24-33.85; p = 0.027). Conclusion: NT-proBNP increased 2 years after breast RT and was associated with baseline level, cardiometabolic, RT fractionation, and endocrine factors. Elevated NT-proBNP could help to identify BC patients at higher risk of subclinical cardiac dysfunction, supporting longitudinal biomarker monitoring in cardio-oncology surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.